Fertility Inc.: The Embryo Editing Dinner

The Journal. Podcast Recap

Published:

Duration: 25 min

Summary

This episode covers a secretive meeting in Silicon Valley discussing embryo editing for genetically engineering babies. It examines the ethical, scientific, and societal implications of such technology.

What Happened

In late July, a group of Silicon Valley elite and scientists gathered at a luxury restaurant in San Francisco to discuss the future of embryo editing. The dinner, hosted by Brian Armstrong, co-founder and CEO of Coinbase, was centered on the question of how to bring embryo editing to fruition, a technology that involves tweaking an embryo's DNA to potentially engineer a genetically enhanced baby.

Embryo editing has been a hot topic since 2018 when Chinese scientist He Jiankui claimed to have created the world's first genetically edited babies, which sparked international outcry and led to his imprisonment. Many scientists remain concerned about the implications of embryo editing, including heritable genetic changes and the potential for creating 'designer babies' or engaging in eugenics.

Despite its controversial nature, embryo editing continues to attract interest from powerful figures in Silicon Valley. Brian Armstrong and others view it as a way to prevent genetic diseases and even enhance human capabilities, drawing inspiration from the sci-fi film 'Gattaca'. Armstrong has expressed interest in both disease prevention and human enhancement through genetic technology.

Journalist Emily Glaser discovered that a company called 'Preventive' is actively pursuing embryo editing research, with connections to major figures like Brian Armstrong and OpenAI CEO Sam Altman. Preventive has been exploring opportunities to conduct research outside the US, where embryo editing is illegal, including in the UAE.

Preventive's CEO, Lucas Harrington, claims the company is focused on proving the safety of embryo editing before attempting to bring a baby to term. However, they have faced criticism and skepticism from the scientific community, who fear the misuse of the technology.

In parallel to embryo editing, embryo screening has gained traction as a legal alternative in the US. Companies like Orcid and Nucleus offer screening services for genetic traits and disease risks, allowing parents to select embryos with desired characteristics. This technology has raised ethical questions about the potential for eugenics and the accuracy of such tests.

Key Insights

View all The Journal. recaps